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RecoveryThe outcome of ﬁrst episode psychosis (FEP) is highly variable and difﬁcult to predict. We studied prospec-
tively the impact of poor insight and neuropsychological deﬁcits on outcomes in a longitudinal cohort of
127 FEP patients. Participants were assessed on 5 domains of cognitive function and 2 domains of insight
(clinical and cognitive). At 12 months, patients were assessed again for symptom severity and psychosocial
function. Regression analyses revealed that cognitive insight (a measure of self-reﬂectiveness and
self-certainty) was the best baseline predictor of overall psychopathology at 12 months whereas executive
function performance at admission to the study indicated later severity of negative symptoms. Other neuro-
psychological and insight measures were poor predictors of psychosocial function at 1 year. The results sug-
gest that speciﬁc neuropsychological and insight factors have separate predictive capacities indicating that
they are distinct psychological processes in psychosis. Cognitive insight proved to be a useful prognostic in-
dicator, and should be considered for future studies and as a potential focus for treatment.
© 2013 Published by Elsevier B.V.1. Introduction
Evidence suggests that rates of recovery from psychosis vary wide-
ly (Van Os et al., 1996) and efforts have been made to determine early
predictors of outcome by tracking illness course in incident cases from
the ﬁrst episode of psychosis. Outcome itself is multifaceted and one
useful way to differentiate types of outcome is by examining clinical
(cessation of symptoms) and functional (social integration, and occu-
pational well being) domains separately. Putative predictors of out-
come after a ﬁrst episode of psychosis (FEP) include duration of
untreated illness (DUP), pre-morbid functioning, gender and diagno-
sis (Wiersma et al., 2000).
Cognitive impairment, which is apparent at the onset of psychosis
and stable over time, has also proven to be a useful indicator of func-
tional outcome in established schizophrenia(Rund, 1998) but conclu-
sions from ﬁrst episode psychosis spectrum samples are less certain
(Mesholam-Gately et al., 2009; Allott et al., 2011; Bozikas and
Andreou, 2011). In terms of symptom outcome in FEP, cross-sectional
studies show strong associations between poor cognitive function and
negative symptoms (Milev et al., 2005). However, the longitudinal na-
ture of this relationship is not clear.'Connor).
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A less explored question in outcome studies is whether insight
into illness at ﬁrst episode predicts later recovery. Poor ‘clinical
insight’ – awareness the patient has of their illness – is common in
schizophrenia samples and across the psychosis spectrum (David,
1990; Amador et al., 1994). There is growing evidence that good in-
sight is associated with recovery (David, 2004; Lincoln et al., 2007)
and measures of insight can predict outcome at one year (Segarra
et al., 2010) and four year follow-ups (Van Os et al., 1996). However,
few follow-up studies have made use of reliable insight assessment
instruments, but rather have taken single insight items from generic
psychopathology scales.
While many studies in psychosis have focused on illness related
insight, Beck and colleagues distinguish another type of insight
construct called ‘cognitive insight’ which reﬂects a more general
cognitive style, namely a tendency toward ﬂexible thinking and for
one's reasoning to be subject to self-reﬂection(Beck et al., 2004).
The Beck Cognitive Insight Scale (BCIS) is a self-report questionnaire
developed to measure cognitive insight in both clinical and nonclinical
populations (Beck et al., 2004). Several studies, but by no means all
(Riggs et al., 2012) have found correlations between clinical and
cognitive insight. Hence they appear to be tapping related but dif-
ferent concepts. The BCIS has shown good test retest reliability in
schizophrenia suggesting it has trait like properties (Riggs et al., 2012)
while clinical insight has both state and trait like properties (Wiffen
et al., 2010).sight predict outcome in psychosis? Findings from a longitudinal ﬁrst
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Extensive research which has been subjected to systematic review
(Morgan and David, 2004) andmeta-analysis (Aleman et al., 2006) sug-
gests that there is an association between poor clinical insight (as mea-
sured by the Schedule for Assessment of Insight—Expanded (SAI-E)
Kemp and David, 1996) and neuropsychological deﬁcits, especially in
domains of executive function (Aleman et al., 2006). However, such
an association is not always evident (Kemp and David, 1996) and
much of the variance in insight cannot be explained by cognitive
function. Cognitive insight has also been shown to be associated
with various neuropsychological functions (Gilleen et al., 2011; Orfei
et al., 2011). In fact one study investigated this in FEP patients and
found that clinical insight was not associated with neuro-cognition
but cognitive insight was (as measured on the BCIS) (Lepage et al.,
2008). Understanding whether insight and neuropsychological mecha-
nisms are distinct will help determine whether insight measures are
useful for predicting outcome independently.
The aim of this study is to investigatewhether insight factors (clinical
and cognitive) at FEP contribute to prognosis, independent of neuropsy-
chological function. As outcome measures often integrate multiple do-
mains of recovery, it is helpful to specify the association that insight
and cognitive factors have with later outcome. Therefore this study will
examine relationships with three domains of outcome separately;
function (social integration and occupational well being), overall psy-
chopathology, and psychosis related symptoms. We hypothesise that
neuropsychological deﬁcits at onset will be associated with poorer func-
tional outcome whereas insight measures will be associated with symp-
tom related recovery. Speciﬁcally, we hypothesise that good insight at
FEP will predict less severe psychopathology at follow-up. We also spec-
ulate that cognitive insight will be a better predictor of outcome than
clinical insight since it is thought to reﬂect an enduring thinking style
while clinical insight is shaped more by ongoing symptoms and sociali-
zation into a medical model (Beck et al., 2004).2. Method
2.1. Sample
We recruited ﬁrst episode psychosis patients as part of the Nation-
al Institute of Health Research (NIHR) Biomedical Research Centre
(BRC) Genetics and Psychosis study. We approached patients aged
18–65 years appearing to meet DSM-IV criteria for schizophrenia or
related disorder, or affective disorder with psychotic features who
presented to one of 3 south London boroughs' geographical catch-
ment area-based adult mental health services. Eligibility was deter-
mined through examination of the clinical notes of new admissions
and consultation with clinical teams. Inclusion criteria required that
patients have 7 or more consecutive days of psychotic symptom(s)
and were presenting to services for the ﬁrst timewith these symptoms.
Patientswere approached as soon as possible (up to 3 months after ﬁrst
contact). Exclusion criteria were developmental learning disability,
poor English ﬂuency, and a known organic cause for psychosis.2.2. Procedures
Ethical approval was obtained from the local research ethics com-
mittee. All study participants gave full informed consent. Raters were
experienced researchers who were extensively trained and demon-
strated adequate inter-rater reliability on clinical and neuropsycho-
logical assessment (Hallgren, 2012). Participants completed all
measures within 6 months of ﬁrst presentation with services. At
12 months after initial assessments, some research measures were
repeated via clinical notes or face to face interview when available.Please cite this article as: O'Connor, J.A., et al., Does clinical or cognitive in
episode cohort, Schizophr. Res. (2013), http://dx.doi.org/10.1016/j.schres2.3. Baseline assessments
2.3.1. Clinical, pre-treatment, and demographic measures
Information about employment/relationships/living status and
medication, was collected through interview with the patient and
searching clinical records. Diagnosis was made according to DSM-IV
criteria using the Operational Criteria OPCRIT (McGufﬁn et al., 1991)
based on the clinical notes for the month after ﬁrst contact with psy-
chiatric services for psychosis. All diagnoses were carried out by qual-
iﬁed psychiatrists and clinical researchers, subject to comprehensive
training and inter-rater reliability testing. This was shown through
consensus diagnoses meetings and a prerequisite screening of 10 di-
agnostic cases with 100% consistency with previous raters before au-
tonomous ratings using OPCRIT occurred. Due to relatively small
numbers in each diagnostic group, diagnoses were combined to
form non-affective (schizophrenia, schizophreniform and psychosis
NOS) and affective (bipolar, mania or depression with psychosis)
groups. Demographic information about housing, relationship and
employment status 1 year prior to FEP and 1 year after were recorded.
DUP (period between ﬁrst psychotic symptom and initiation of
treatment) was calculated based on full clinical notes (with some infor-
mant interviews) of each patient.
The Global Assessment of Functioning—GAF, which is a single rat-
ing scale from 1 to 100 (a low score indicating poorer functioning)
(American, Psychiatric Association, 1994) was used to rate both se-
verity of symptoms and disability. We assigned two separate ratings
on the GAF based on dimensions of psychiatric symptoms and psy-
chological, social and occupational function. To rate speciﬁc psychotic
symptoms, the Positive and Negative Syndrome Scale (PANSS) was
used (Kay et al., 1987). The PANSS was scored on a clinical interview,
and symptoms rated on a Likert scale (1–7); high scores indicate
more severe psychotic symptoms.
2.3.2. Insight measures
Clinical insight was measured with the SAI-E (Kemp and David,
1996). This scale measures three linked but separable dimensions of
insight: awareness of illness; need for treatment; and the relabeling
of symptoms as abnormal. It is an observer rated, semi-structured in-
terview. Researchers were highly trained by the scale author before
using the scale with participants, and were familiar with the clinical
presentation of the patient. Inter-rater reliability following this train-
ing has been shown to be excellent (Morgan et al., 2010); high scores
represent better insight.
Cognitive insight, a type of metacognitive measure (David et al.,
2012) was quantiﬁed using the BCIS (Beck et al., 2004). This is a 15
item self-report scale, with items rated from ‘do not agree at all’ to
‘agree completely’. There are two subscales: ‘self-reﬂectiveness’,
which assesses willingness to accept fallibility and external feedback,
as well as recognising dysfunctional reasoning style (e.g. ‘my unusual
experiences may be due to my being extremely upset or stressed’)
(9 items), and ‘self-certainty’, which assesses overconﬁdence (e.g. ‘I
can trust my judgment at all times’) (6 items). High self-reﬂectiveness
and low self-certainty are thought to indicate ‘good’ cognitive insight.
Participants rated agreement on a 7-point Likert scale. This aimed to in-
crease the sensitivity of the original measure, which used a 4-point
scale.
2.3.3. Neuropsychological measures
All participantswere assessed in the followingﬁve domains: General
cognitive function: Full-scale IQ was derived from the Wechsler Adult
Intelligence Scale—Third Edition (WAIS III) from the Information, Digit
Span, BlockDesign,Matrix Reasoning and Digit Symbol Coding subtests.
Verbal Memory: TheWechsler Memory Scale—Third Edition (WMS-III)
logical memory test at a delayed (30-min delay) time point was used.
Nonverbal Memory: as for Verbal Memory but using visual reproduc-
tion. Executive function and working memory: Trails B; the Spatialsight predict outcome in psychosis? Findings from a longitudinal ﬁrst
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Automated Battery (CANTAB); and a verbal semantic ﬂuency test. Pro-
cessing speed: The Trails A. Individual test scores were converted into
age standardised scores (WAIS and WMS III and SWM) or raw score
(Trails, Semantic Fluency) and transformed if distributions were not
normal (reference list for the above tests available from the authors
on request).
2.4. Follow-up assessments
GAF ratings were scored again 12 months after patients were ini-
tially assessed. Researchers used clinical notes to assess both symp-
tom and function aspects of the GAF (108 participants) or when
available, the assessment was supplemented by a face to face inter-
view (19 participants). The reduced ﬁgure for interview was due to
strict time frame criteria for GAF (2 week window either side of base-
line assessment +1 year) so in the majority of cases, records only
were used. Researchers involved in rating GAF via notes completed
intensive reliability checks (Cronbach alpha ~0.9). PANSS scores via
interview were also collected at or just beyond the 12 month
follow-up point (average 14.9 months). The number of participants
with PANSS scores at 12 months dropped to 72 because it required
clients to have a face to face interview. PANSS scores were collected at
or just beyond the 12 month follow-up point (average 14.9 months).
The same raters were involved in the GAF and PANSS interviews and re-
cord based GAF assessment to assist reliability.
2.5. Data analysis
Pearson's correlations were conducted to evaluate the relationship
between baseline measures (symptoms, functioning, and neuropsy-
chological and insight scores) with functional and symptomatic
outcome at 12 month FU. No correction for multiple testing was ap-
plied as these correlations were exploratory and served to select vari-
ables for regression analysis. Correlated factors (r > .25) were
entered into hierarchical multiple regressions in order to estimate a
useful predictor model. Insight measures taken at entry into the
studywere the independent variables and symptomand functional out-
come at 12 month follow-up were the dependent variables. Other fac-
tors which correlated highly to the outcome measures were entered
into the model as covariates.
3. Results
3.1. Description of sample
Of the 152 patients enrolled in the BRC studywith completed neuro-
psychological assessments, 127 were assessed at 1 year follow-up ei-
ther by face to face interview or via clinical records giving a
completion rate of 83.6%. The reasons for drop out included leaving
the country (n = 9) disengagement from clinical team and/or refusal
to take part in study interview (n = 11), clinical notes not attainable
and/or refusal to take part in study interview (n = 3) and suicide
(n = 2). There were no signiﬁcant differences between those who
completed the study from those that dropped out in terms of gender,
age, ethnicity, education or baseline symptoms (all t = −1.206 to
.447, P = .2 to .8). The DSM IV diagnoses for the sample were schizo-
phrenia (23.6%), schizophreniform disorder (30%), schizoaffective-
depressed (4.7%), schizoaffective-bipolar (6.3%), major depression
with psychosis (10.2%), manic episode with psychosis (12.5%) and psy-
chosis NOS (12.6%).
At inclusion, 86% of patients were prescribed antipsychotic medi-
cation, and this decreased to 76% at 12 month follow-up. Time
spent in psychiatric hospital varied widely with an average inpatient
stay of 71 days. From 12 months prior to illness onset to 12 months
after FEP, rates of unemployment in the cohort almost doubled toPlease cite this article as: O'Connor, J.A., et al., Does clinical or cognitive in
episode cohort, Schizophr. Res. (2013), http://dx.doi.org/10.1016/j.schres.68%. Around 60% of patients were single and almost a third, living
alone with minimal changes at follow-up. Further description of the
cohort is given in Table 1.
3.2. Correlation analysis
Signiﬁcant inter-correlations fromTime1 (ﬁrst contactwith services)
and at Time 2 (12 month FU) are described below. Collinearity of predic-
tor variables was low (tolerance of 0.75 and above).
3.2.1. Insight and neuropsychology
Our clinical insight factor (SAI-E scores) did not correlate with IQ
scores, but showed moderate associations with Verbal Memory
scores (r = .42) and Digit Symbol Coding (r = .31). Clinical insight
also showed weak associations with Verbal Fluency (.292), Matrix
Reasoning (r = .21), Trails A (r = − .27) and Trails B (r = − .25).
Cognitive insight (BCIS) associated most strongly with executive
function tasks, (Verbal Fluency r = .40 Trails B r = − .34 SWM strat-
egy score, r = − .31) and Verbal Memory (r = .245).
3.2.2. Neuropsychological associations with outcome
Baseline neuropsychological variables were shown to be correlat-
ed, albeit weakly with negative symptoms at 12 months: verbal tasks
including WAIS composite IQ r = − .25, Information r = − .24, Ver-
bal Memory r = − .27, Verbal Fluency r = − .26 and executive func-
tion tasks (SWM strategy score r = − .31; Trails B, r = .28). Digit
Symbol Coding and Verbal Fluency were associated with 12 month
functional function (r = .195, r = .21 respectively).
3.2.3. Insight and outcome
Clinical insight was associated with both symptom and function
GAF domains at 12 months (both r = .26). Cognitive insight also cor-
related with GAF 12 month symptom severity (r = .32) and psycho-
social function (r = .23). Insight factors were not associated
speciﬁcally with positive or negative symptoms at follow-up. No vari-
ables of interest associated with positive symptoms at 12 month
follow-up.
3.3. Regression analysis
On the bases of correlation ﬁndings, a series of hierarchical multi-
ple regressions was carried out to compare the variance in outcome
that can be explained by insight and neuropsychological factors
after controlling for possible confounders. Regression models were
created to analyse predictors of different aspects of outcome. These
are function (social integration and occupational well-being), overall
psychopathology, and psychosis-related symptoms.
3.3.1. Prediction of general psychopathology
Gender, diagnoses, DUP and ethnicity were entered into the model
ﬁrst, followed by baseline negative symptoms, then cognitive and
clinical insight measures. Neuropsychological factors were not en-
tered into the regression as they did not correlate with the GAF symp-
tom scale. In this model cognitive insight independently contributed
to the model, and together with negative symptoms explained 21%
of variance in outcome F (2, 57) = 8.602, P b .01. Speciﬁcally each
scale increase on the BCIS scale corresponds to half a unit improve-
ment on the GAF symptom scale at 12 months. See Table 2a for de-
tails. Self-reﬂectiveness and self-certainty provided equivalent
though opposite contributions to the model (t = −1.719 and 1.723
respectively). The composite score correlated better with the GAF
symptom outcome than did the scales individually.
3.3.2. Prediction of psychosis-related symptoms
Insight measures were not well correlated with negative symp-
toms at 12 months, but neuropsychological factors were (verbal andsight predict outcome in psychosis? Findings from a longitudinal ﬁrst
2013.06.005
Table 1
Description of sample over time.
Demographic/symptom data Baseline sample
Age, years M = 29.75 (8.95)
Gender 69% male
Years of education M = 13.28 years
Level of education obtained Postgraduate: 3%
Degree: 17%
A levels:22%
NVQ/vocational: 22%
GCSE'S: 20%
No qualiﬁcations: 16%
Ethnicity Black African/Caribbean: 40%
White British: 27%
White other: 11%
Asian: 6%
Other: 16%
IQ N: 152
FSIQ: 89.65 (16.15)
PIQ: 86.93 (15.80)
VIQ: 94.05 (16.08)
Progress Baseline 12 month FU
PANSS ratings n = 138 n = 72
Positive M = 14.65 (6.0) Positive M = 11.50 (4.9)
Negative: M = 14.90 (6.3) Negative: M = 14.11 (5.9)
GAF scores n = 130 n = 127
Symptoms: 48.78 (20.23) Symptoms: 57.73 (20.4)
Function: 57.03 (17.5) Function: 59.23 (19.5)
Medication n = 145 n = 123
Antipsychotics: 53.3% Antipsychotics: 49%
– Oral 98.5% – Oral 89%
– Depot 1.5% – Depot 9%
Antipsychotics/
antidepressant: 18%
Antipsychotics/
antidepressant: 21%
Anti-psychotic/
tranquilisers: 19%
Anti-psychotic/
tranquilisers: 6%
Anti-depressants 2% Anti-depressants 5%
Lithium: 0% Lithium: 2%
Other combinations: 2.9% Other combinations: 9%
None: 4.8% None: 8%
Psychiatric hospital
admission days
during 1 year
follow-up
71.09 days (79.15)
Range = 0 to 365
Social
circumstances
Year prior to onset 12 month follow-up
Relationship status n = 147 n = 126
Single 60% Single 71%
Married/living with
someone 20%
Married/living with
someone 20%
In a steady relationship 20% In a steady relationship 9%
Employment status n = 150 n = 127
Unemployed 38% Unemployed 68%
Student 11% Student 11%
Employed full time 35% Employed full time 8%
Employed part time 16% Employed part time 13%
Living status n = 149 n = 126
Alone 30% Alone 20%
Alone with children 6% Alone with children 5%
With partner 8% With partner 5%
With partner & children 12% With partner & children 15%
Parents 26% Parents 20%
Other family 5% Other family 4%
Friends 9% Friends 5%
Other 4% Other 28%
Psychiatric hospital 50%
Supported
Accommodation: 33%
Prison: 3%
Other: 14%
Table 2a
Regression showing the ability of insight factors to predict symptom severity.
Std beta t P
Final model
Cognitive insight 0.340 2.861 0.006
Baseline negative symptoms −0.305 −2.563 0.013
Excluded variables
Gender 0.164 1.370 0.176
Diagnosesa 0.193 1.558 0.125
DUP 0.109 0.886 0.380
Ethnicityb −0.115 − .943 0.380
Clinical insight 0.091 0.673 0.504
a Non-affective vs affective.
b White vs Black.
Table 2b
Regression showing the ability of neuropsychological factors to predict negative
symptoms.
Std beta t P
Final model
Trails B 0.336 2.652 0.011
Baseline negative symptoms 0.358 2.639 0.012
Excluded variables
DUP 0.203 1.498 0.142
Gender −0.257 −2.041 0.048
Diagnosesa −0.066 −0.491 0.626
Ethnicityb 0.175 1.345 0.186
Verbal Fluency 0.021 0.145 0.885
WAIS information 0.107 0.164 0.449
Verbal Memory −0.102 −0.664 0.551
a Non-affective vs affective.
b White vs Black.
4 J.A. O'Connor et al. / Schizophrenia Research xxx (2013) xxx–xxxexecutive function tasks). These were entered stepwise into a model
along with gender, diagnoses, DUP and ethnicity and baseline nega-
tive symptoms. In this case, Trails B alongside negative symptoms
was predictive of negative symptoms at 12 months; F (1, 34) =Please cite this article as: O'Connor, J.A., et al., Does clinical or cognitive in
episode cohort, Schizophr. Res. (2013), http://dx.doi.org/10.1016/j.schres11.33, P b .002, accounting for 23% of outcome variance. Speciﬁcally,
a difference in speed of 10 s on the trails task predicted a correspond-
ing shift of nearly 4 points on the PANSS negative symptoms scale.
Faster performance on the Trails B was associated with fewer nega-
tive symptoms at 12 months. See Table 2b for details.
3.3.3. Prediction of functional outcome
The usefulness of both insight measures to predict functional out-
come was assessed in a regression model after controlling for possible
confounders (gender, diagnoses, DUP, ethnicity, baseline function and
baseline negative symptoms) and highly correlated neuropsycholog-
ical variables (Digit Symbol Coding and Verbal Fluency). Baseline neg-
ative symptoms, ethnicity and gender accounted for 39% of variance
in function at 12 months F (3, 44) = 10.47, P b 0001. Insight and
neuropsychological measures were excluded from the ﬁnal model
as they did not account for variance to a signiﬁcant level. Negative
symptoms alone accounted for 22% of the variance, with a decreased
unit PANSS score corresponding to an increase in 12 month function
of 1.6 GAF points. Ethnicity added another 10% of variance into the
model, with white patients showing 14 points better function on
the GAF compared to black and minority ethnic groups at follow-up.
Finally being female led to improvements in functional outcome by
12 points on the GAF scale. See Table 3 for details.
4. Discussion
In line with our hypotheses, our data suggest that the cognitive pro-
cesses underlying neuropsychological performance and level of insight
account for separate variance in recovery from FEP. Poor cognitive in-
sight was associated with more severe psychopathology at 12 months,
which supports our prediction that cognitive insight is better associated
with outcome than clinical insight.We hypothesised that neuropsycho-
logical deﬁcits at onset would be associated with poorer functionalsight predict outcome in psychosis? Findings from a longitudinal ﬁrst
.2013.06.005
Table 3
Regression showing the ability of demographic, clinical and cognitive factors to predict
functional outcome.
Std beta t P
Final model
Baseline negative symptoms −0.474 −4.012 0.001
Ethnicitya − .316 −2.681 0.011
Gender 0.278 2.349 0.024
Excluded variables
Diagnosesb .228 1.818 0.077
DUP −0.219 −1.881 0.067
Baseline function .163 1.297 0.202
Verbal Fluency 0.085 0.637 0.528
Digit Symbol Coding 0.030 .191 0.850
Clinical insight 0.100 .699 0.489
Cognitive insight 0.144 1.159 0.253
a White vs Black.
b Non-affective vs affective.
5J.A. O'Connor et al. / Schizophrenia Research xxx (2013) xxx–xxxoutcome however, functional outcomewas predicted by neither insight
nor neuropsychological factors. Rather, only negative symptoms, as
rated by PANSS scores were associated with baseline neuropsychology
performance, predicted mainly by executive function.
4.1. Cognitive insight and outcome
Cognitive insight did predict later psychopathology based on out-
come scores of the GAF. While previous studies have shown that BCIS
is associated with positive symptoms (Pedrelli et al., 2004; Bora et al.,
2007) our results did not indicate a direct association with negative or
positive symptoms. This perhaps was due to reduced numbers on the
PANSS assessment (96) compared to GAF (117). Another plausible ex-
planation for this ﬁnding may have to do with the fact that the PANSS
focusses on ‘positive and negative psychotic symptoms’ rather than
generalised psychopathology. Indeed past research suggests that the as-
sociation with cognitive insight differs between speciﬁc positive symp-
toms, such that poor cognitive insight is associated with delusional
thinking not hallucinations (Engh et al., 2010) Other studies have also
failed to ﬁnd a relationship between cognitive insight and PANSS posi-
tive symptoms (Favrod et al., 2008; Tranulis et al., 2008; Uchida et al.,
2009). The GAF is a measure of generalised psychopathology and so
other factors such as mood may be an important factor inﬂuencing
the positive association between cognitive insight and outcome. For ex-
ample, research has found positive correlations between cognitive in-
sight and anxiety (Colis et al., 2006).
In a review, Riggs et al. (2012) emphasise that research exploring
associations between BCIS and symptoms has produced mixed results
and that this is a relatively new ﬁeld of research, precluding ﬁrm con-
clusions (Riggs et al., 2012). In spite of these considerations, our re-
sults indicate that cognitive insight is worthy of further examination
as a potentially useful factor for prognoses and treatment. We did
not examine change in BCIS over time but it would be interesting to
see if particular elements of cognitive insight may be tackled thera-
peutically to improve symptom outcome. For example, using cogni-
tive behavioural therapy (CBT) to challenge rigid thinking styles and
encourage self reﬂection could be measured as improvements on
the BCIS (Granholm et al., 2006; Perivoliotis et al., 2010).
4.2. Clinical insight and outcome
Clinical insight as measured by the SAI-E was not a predictor of out-
come over time in this study (cf: R J. Drake et al., 2007; Startup et al.,
2010). This ﬁnding aligns with a review of the literature which found
that there is good evidence that insight predicts relapse and
readmission in FEP, but less for links between insight and later symp-
toms or function (Drake, 2008) The lack of association across time indi-
cates that clinical insight may be too ﬂuid a construct to be a usefulPlease cite this article as: O'Connor, J.A., et al., Does clinical or cognitive in
episode cohort, Schizophr. Res. (2013), http://dx.doi.org/10.1016/j.schres.prognostic indicator in prospective studies especially in the early
phase of the illness, presumably because the patient, and indeed their
careers are struggling to make sense of their experiences in terms of a
pathological process (McGorry and McConville, 1999; Lappin et al.,
2007). Furthermore, in order to maximise statistical power, we only
evaluated the SAI-E composite score while ﬁndings from a study from
Taiwan showed that insight into need for treatment was predictive of
1 year outcome, but insight into psychotic experience was not (Yen et
al., 2002). To further complicate matters, insight into illness appears
to manifest differently across diagnostic categories (Drake, 2008).
As noted above, considering that clinical insight is closely attuned
with symptoms at the acute phase of psychosis, it may be useful to
measure the prospective value of insight at a time where psychotic
symptoms are more stable. For example, Wiffen and colleagues
showed that insight improves over a 1 year period, and that there
was a corresponding change in symptom severity in a sample of
670 stable patients with schizophrenia or schizoaffective disorder en-
rolled in a clinical trial (Wiffen et al., 2010) Other research has also
shown a correlation between change in insight and global improve-
ment of symptoms in 614 patients with schizophrenia(Gharabawi et
al., 2006) similarly, early change in symptoms and insight predicted
outcome 1 year later in FEP in Vellore, South India (Saravanan et al.,
2010) Finally, the CATIE study revealed that improvement in insight
was also associated with decreased severity of symptoms, having ad-
justed for baseline after 18 months (Mohamed et al., 2009).
4.3. Neuropsychology and outcome
This study identiﬁed an association between the Trails B task and
negative symptoms at 12 months consistent with prior research indi-
cating that negative symptoms and cognition overlap, even in FEP
(Malla et al., 2002; Milev et al., 2005). Factors that tend to cluster
with prominent negative symptoms such as insidious onset and a
schizophrenia diagnosis also did not take away the association
shown between poor Trails B performance and enduring negative
symptoms. We found no association between negative symptoms
and Trails A. Our results suggest that the negative dimension of psy-
chopathology is speciﬁcally associated with working memory and ex-
ecutive functions (both of which Trails B can index) rather than mere
processing speed, and supports previous follow-up studies (Green et
al., 2000; Fujii and Wylie, 2003).
4.4. Functional outcome
Negative symptoms at baseline were the best predictor of outcome
in the psychosocial domain. Being female and of white ethnicity were
also associated with better psychosocial functioning. After accounting
for these factors, insight and neuropsychological performance were
not associatedwith function at 12 months. Perhaps the impact of cogni-
tion on outcome does not manifest strongly until later in illness course.
Indeed for all patients, disability is liable to endure long after cessation
of symptoms and perhaps outcome trajectories are not differentiated
enough at one year to identify reliable cognitive predictors.
4.5. Limitations
Our inability to identify links between neuropsychological or in-
sight factors with functional outcome may in part be due to the use
of only one global functional outcome measure and the study could
have beneﬁted from analysing speciﬁc real life outcome indicators
(but see Allott et al., 2011). In light of an association between cogni-
tive insight and general psychopathology rather than psychotic
symptoms, it would have been informative to have evaluated mood
and other non-psychotic symptoms at follow-up since low mood
tends to link with increased self evaluation (Crumlish et al., 2005;
David et al., 2012) Also, our neuropsychological battery was brief, sosight predict outcome in psychosis? Findings from a longitudinal ﬁrst
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tery, particularly one which had a wider range of executive function
tasks, may have been more sensitive. Finally, while statistical power
concerns prohibited us from including more variables in the analysis,
important factors such as pre-morbid adjustment, substance abuse
and medication could be important confounders in this study.
4.6. Conclusions
We have shown an association between aspects of outcome fol-
lowing an episode of psychosis and a relatively novel measure of
self appraisal style known as cognitive insight. The positive relation-
ship over time between cognitive insight and psychopathology
suggests a causal role for meta-cognition on later recovery from psy-
chosis. Intervention studies to explore the effect of change to cogni-
tive insight might help clarify the relationship as well as providing a
novel focus for treatment studies.
Role of funding source
The study was supported by funding from the NIHR Biomedical Research Centre
for Mental Health at the South London and Maudsley NHS Foundation Trust and Insti-
tute of Psychiatry, King's College London. The funding sources had no further role in
the study design, methods, analysis, interpretation of data, writing of the manuscript,
and in the decision to submit the paper for publication. The views expressed in this
publication are those of the authors and not necessarily those of the funding sources.
Contributors
The Genes and Psychosis (GAP) study is overseen by RM, AD MD and SB. JO and
BW designed the present study using data from the GAP, and selected the measures.
JO collected, scored and input data, analysed and interpreted the ﬁndings and wrote
the manuscript. AD, BW and CJ assisted in the interpretation of the ﬁndings and
commented on the manuscript. Authors BW, LF, CJ, AK and BW recruited participants,
and collected and scored data.
Conﬂict of interest
All authors declare that they have no conﬂicts of interest.
Acknowledgements
We are grateful for the support of all GAP researchers and Principle Investigators for
their contribution and support of this study. We also acknowledge support from the
Department of Health via the National Institute for Health Research (NIHR) Specialist
Biomedical Research Centre for Mental Health award to South London and Maudsley
NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London.
References
Aleman, A., Agrawal, N., Morgan, K.D., David, A.S., 2006. Insight in psychosis and neu-
ropsychological function: meta-analysis. Br. J. Psychiatry 189 (3).
Allott, K., Liu, P., Profﬁtt, T.-M., Killackey, E., 2011. Cognition at illness onset as a predic-
tor of later functional outcome in early psychosis: systematic review and method-
ological critique. Schizophr. Res. 125 (3), 221–235.
Amador, X.F., Flaum, M., Andreasen, N.C., Strauss, D.H., Yale, S.A., Clark, S.C., et al., 1994.
Awareness of illness in schizophrenia and schizoaffective and mood disorders.
Arch. Gen. Psychiatry 51 (10), 826–836.
American, Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental
Disorders, 4th ed. (Washington DC.).
Beck, A., Baruch, E., Balter, J.M., Steer, R.A., Warman, D.M., 2004. A new instrument for mea-
suring insight: the Beck Cognitive Insight Scale. Schizophr. Res. 68 (2–3), 319–329.
Bora, E., Erkan, A., Kayahan, B., Veznedaroglu, B., 2007. Cognitive insight and acute psy-
chosis in schizophrenia. Psychiatry Clin. Neurosci. 61 (6), 634–639.
Bozikas, V.P., Andreou, C., 2011. Longitudinal studies of cognition in ﬁrst episode psy-
chosis: a systematic review of the literature. Aust. N. Z. J. Psychiatry 45, 93–108.
Colis, M.J., Steer, R.A., Beck, A.T., 2006. Cognitive insight in inpatients with psychotic, bipo-
lar, and major depressive disorders. J. Psychopathol. Behav. Assess. 28 (4), 242–249.
Crumlish, N., Whitty, P., Kamali, M., Clarke, M., Browne, S., McTigue, O., et al., 2005.
Early insight predicts depression and attempted suicide after 4 years in ﬁrst-
episode schizophrenia and schizophreniform disorder. Acta Psychiatr. Scand. 112
(6), 449–455.
David, A., 1990. Insight and psychosis. Br. J. Psychiatry 156, 798–808.
David, A., 2004. The clinical importance of insight: an overview, In: Amador, David
(Eds.), Insight and Psychosis: Awareness of Illness in Schizophrenia and Related
Disorders, 2nd ed. Oxford University Press, Oxford, pp. 359–392.
David, A., Bedford, N., Wiffen, B., Gilleen, J., 2012. Failures of metacognition and lack of
insight in neuropsychiatric disorders. Philos. Trans. R. Soc. B Biol. Sci. 367 (1594),
1379–1390.
Drake, R.J., 2008. Insight into illness: impact on diagnosis and outcome of nonaffective
psychosis. Curr. Psychiatry Rep. 10, 210–216.Please cite this article as: O'Connor, J.A., et al., Does clinical or cognitive in
episode cohort, Schizophr. Res. (2013), http://dx.doi.org/10.1016/j.schresDrake, R.J., Dunn, G., Tarrier, N., Bentall, R.P., Haddock, G., Lewis, S., 2007. Insight as a
predictor of the outcome of ﬁrst-episode nonaffective psychosis in a prospective
cohort in England. J. Clin. Psychiatry 68 (1), 81–86.
Engh, J.A., Friis, S., Birkenaes, A.B., Jonsdottir, H., KlungsÃ¸yr, O., Ringen, P.A., et al., 2010.
Delusions are associated with poor cognitive insight in schizophrenia. Schizophr.
Bull. 36 (4), 830–835.
Favrod, J., Zimmermann, G., Raffard, S., Pomini, V., Khazaal, Y., 2008. The Beck Cognitive
Insight Scale in outpatients with psychi-atric disorders: further evidence from a
French-speaking sample. Can. J. Psychiatry 53, 783–787.
Fujii, D.E., Wylie, A.M., 2003. Neurocognition and community outcome in schizophre-
nia: long-term predictive validity. Schizophr. Res. 59 (2–3), 219–223.
Gharabawi, G., Lasser, R.A., Bossie, C.A., Zhu, Y., Amador, X., 2006. Insight and its relation-
ship to clinical outcomes inpatientswith schizophrenia or schizoaffective disorder re-
ceiving long-acting risperidone. Int. Clin. Psychopharmacol. 21 (4), 233–240.
Gilleen, J., Greenwood, K., David, A.S., 2011. Domains of awareness in schizophrenia.
Schizophr. Bull. 37 (1), 61–72.
Granholm, E., Auslander, L., Gottlieb, J., McQuaid, J., McClure, F., 2006. Therapeutic fac-
tors contributing to change in cognitive-behavioral group therapy for older per-
sons with schizophrenia. J. Contemp. Psychother. 36 (1), 31–41.
Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., 2000. Neurocognitive deﬁcits and functional
outcome in schizophrenia: are we measuring the “right stuff”? Schizophr. Bull. 26
(1), 119–136.
Hallgren, K.A., 2012. Computing inter-rater reliability for observational data: an over-
view and tutorial. Tutorials Quant. Methods Psychol. 8 (1), 23–34.
Kay, S., Fiszbein, A., Opler, L., 1987. The positive and negative syndrome scale (PANSS)
for schizophrenia. Schizophr. Bull. 13.
Kemp, R., David, A.S., 1996. Psychological predictors of insight and compliance in psy-
chotic patients. Br. J. Psychiatry 169 (4), 444–450.
Lappin, J.M., Morgan, K.D., Valmaggia, L.R., Broome, M.R., Woolley, J.B., Johns, L.C., et al.,
2007. Insight in individuals with an At Risk Mental State. Schizophr. Res. 90 (1–3),
238–244.
Lepage, M., Buchy, L., Bodnar, M., Bertrand, M.-C., Joober, R., Malla, A., 2008. Cognitive
insight and verbal memory in ﬁrst episode of psychosis. Eur. Psychiatry 23 (5),
368–374.
Lincoln, T.M., Lullmann, E., Rief, W., 2007. Correlates and long-term consequences of
poor insight in patients with schizophrenia. A systematic review. Schizophr. Bull.
33 (6), 1324–1342.
Malla, A.K., Norman, R.M.G., Mancanda, R., Townsend, L., 2002. Symptoms, cognition,
treatment adherence and functional outcome in ﬁrst-episode psychosis. Psychol.
Med. 32 (06), 1109–1119.
McGorry, P.D., McConville, S.B., 1999. Insight in psychosis: an elusive target. Compr.
Psychiatry 40 (2), 131–142.
McGufﬁn, P., Farmer, A., Harvey, I., 1991. A polydiagnostic application of operational
criteria in studies of psychotic illness: development and reliability of the OPCRIT
system. Arch. Gen. Psychiatry 48, 764–770.
Mesholam-Gately, R.I., Giuliano, A.J., Goff, K.P., Faraone, S.V., Seidman, L.J., 2009.
Neurocognition in ﬁrst-episode schizophrenia: a meta-analytic review. Neuropsy-
chology 23 (3), 315–336.
Milev, P., Ho, B.-C., Arndt, S., Andreasen, N.C., 2005. Predictive values of neurocognition
and negative symptoms on functional outcome in schizophrenia: a longitudinal
ﬁrst episode study with 7-year follow up. Am. J. Psychiatry 162, 495–506.
Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., Lieberman, J.A., 2009.
Cross-sectional and longitudinal relationships between insight and attitudes to-
ward medication and clinical outcomes in chronic schizophrenia. Schizophr. Bull.
35 (2), 336–346.
Morgan, K., David, A., 2004. Neuropsychological studies of insight in patients with psy-
chotic disorders, In: Amador, X., David, A. (Eds.), Insight and Psychosis, 2nd ed. Oxford
University Press, London.
Morgan, K.D., Dazzan, P., Morgan, C., Lappin, J., Hutchinson, G., Suckling, J., et al., 2010.
Insight, grey matter and cognitive function in ﬁrst-onset psychosis. Br. J. Psychiatry
197 (2), 141–148.
Orfei, M.D., Caltagirone, C., Cacciari, C., Assogna, F., Spalletta, G., 2011. The neuropsy-
chological correlates of cognitive insight in healthy participants. Appl. Cogn.
Psychol. 25 (6), 927–932.
Pedrelli, P., McQuaid, J.R., Granholm, E., Patterson, T.L., McClure, F., Beck, A.T., et al.,
2004. Measuring cognitive insight in middle-aged and older patients with psychot-
ic disorders. Schizophr. Res. 71 (2–3), 297–305.
Perivoliotis, D., Grant, P.M., Peters, E.R., Ison, R., Kuipers, E., Beck, A.T., 2010. Cognitive
insight predicts favorable outcome in cognitive behavioral therapy for psychosis.
Psychosis: Psychol. Soc. Integr. Approaches 21 (1), 23–33.
Riggs, S.E., Grant, P.M., Perivoliotis, D., Beck, A.T., 2012. Assessment of cognitive insight:
a qualitative review. Schizophr. Bull. 36 (2).
Rund, B.R., 1998. A review of longitudinal studies of cognitive functions in schizophre-
nia patients. Schizophr. Bull. 24 (3), 425–435.
Saravanan, B., Jacob, K.S., Johnson, S., Prince, M., Bhugra, D., David, A.S., 2010. Outcome
of ﬁrst-episode schizophrenia in India: longitudinal study of effect of insight and
psychopathology. Br. J. Psychiatry 196 (6), 454–459.
Segarra, R., Ojeda, N., J, P., Garcia, J., Rodriguez-Morales, A., Ruiz, I., et al., 2010. Longitudinal
changes of insight in ﬁrst episode psychosis and its relation to clinical symptoms,
treatment adherence and global functioning: one-year follow-up from the Eiffel
study. Eur. Psychiatry 27 (1), 43–49.
Startup, M., Jackson, M., Startup, S., 2010. Insight, social functioning and readmission to
hospital in patients with schizophrenia-spectrum disorders: prospective associa-
tions. Psychiatry Res. 178 (1), 17–22.
Tranulis, C., Lepage, M., Malla, A., 2008. Insight in ﬁrst episode psychosis: who is
measuring what? Early Interv. Psychiatry 2 (1), 34–41.sight predict outcome in psychosis? Findings from a longitudinal ﬁrst
.2013.06.005
7J.A. O'Connor et al. / Schizophrenia Research xxx (2013) xxx–xxxUchida, T., Matsumoto, K., Kikuchi, A., et al., 2009. Psychometric properties of the
Japanese version of the Beck Cognitive Insight Scale: relation of cognitive insight
to clinical insight. Psychiatry Clin. Neurosci. 63, 291–297.
Van Os, J., Fahy, T., Jones, P., Harvey, I., Sham, P., Lewis, S., et al., 1996. Psychopatholog-
ical syndromes in the functional psychoses: associations with course and outcome.
Psychol. Med. 26 (1), 163–178.
Wiersma, D., Wanderling, J., Dragomirecka, E., Ganev, K., Harrison, G., An Der Heiden, W., et
al., 2000. Social disability in schizophrenia: its development and prediction over
15 years in incidence cohorts in six European centres. Psychol.Med. 30 (5), 1155–1167.Please cite this article as: O'Connor, J.A., et al., Does clinical or cognitive in
episode cohort, Schizophr. Res. (2013), http://dx.doi.org/10.1016/j.schres.Wiffen, B.D.R., Rabinowitz, J., Lex, A., David, A.S., 2010. Correlates, change and ‘state or
trait’ properties of insight in schizophrenia. Schizophr. Res. 122 (1–3), 94–103.
Yen, C.-F., Yeh, M.-L., Chen, C.-S., Chung, H.-H., 2002. Predictive value of insight for
suicide, violence, hospitalization, and social adjustment for outpatients with
schizophrenia: a prospective study. Compr. Psychiatry 43 (6), 443–447.sight predict outcome in psychosis? Findings from a longitudinal ﬁrst
2013.06.005
